Bisphosphonates and Connexin 43: A Critical Review of Evidence

REFERENCES

• Amano K, Ishiguchi M, Aikawa T, Kimata M, Kishi N, Fujimaki T, Murakami A, Kogo M (2012). Cleft lip in oculodentodigital dysplasia suggests novel roles for connexin43. J Dent Res. 91: S38–S44.
   PubMed Web of Science ®Google Scholar
• Balena R, Toolan B, Shea M, Markatos A, Myers E, Lee S, Opas E, Seedor J, Klein H, Frankenfield D (1993). The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 92: 2577.
   PubMed Web of Science ®Google Scholar
• Bellido T, Plotkin LI (2011). Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 49: 50–55.
   PubMed Web of Science ®Google Scholar
• Boland R, Santillan G., Katz S, Morelli S, Stockman G, Roldan E (2003). Modulation of [Ca2+] in osteoblastic cells by olpadronate and amino-olpadronate. Protein phosphatases as possible target of bisphosphonates. Biocell. 27: 132.
   Google Scholar
• Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ (2002). Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res. 17: 1139–1147.
   PubMed Web of Science ®Google Scholar
• Brumsen C, Hamdy NA, Papapoulos SE (1997). Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine. 76: 266–283.
   PubMed Web of Science ®Google Scholar
• Cao F, Eckert R, Elfgang C, Nitsche JM, Snyder SA, Hulser DF, Willecke K, Nicholson BJ (1998). A quantitative analysis of connexin-specific permeability differences of gap junctions expressed in HeLa transfectants and Xenopus oocytes. J Cell Sci. 111: 31–43.
   PubMed Web of Science ®Google Scholar
• Carr G, Sayer J, Simmons N (2008). Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem. 20: 507–516.
   Web of Science ®Google Scholar
• Chaible LM, Sanches DS, Cogliati B, Mennecier G, Dagli MLZ (2011). Delayed osteoblastic differentiation and bone development in Cx43 knockout mice. Toxicol Pathol. 39: 1046–1055.
   PubMed Web of Science ®Google Scholar
• Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997). Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 100: 1475.
   PubMed Web of Science ®Google Scholar
• Evans WH, Martin PE (2002). Gap junctions: structure and function (Review). Mol Membr Biol. 19: 121–136.
   PubMed Web of Science ®Google Scholar
• Ezra A, Golomb G (2000). Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 42: 175–195.
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Boonen S (2005). The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 27: 1–11.
   PubMed Web of Science ®Google Scholar
• Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998). Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 339: 947–952.
   PubMed Web of Science ®Google Scholar
• Goodenough DA, Paul DL (2003). Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 4: 285–295.
   PubMed Web of Science ®Google Scholar
• Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL (2010). Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. 46: 666–672.
   PubMed Web of Science ®Google Scholar
• Gurley KA, Reimer RJ, Kingsley DM (2006). Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 79: 1017–1029.
   PubMed Web of Science ®Google Scholar
• Horie D, Takahashi M, Aoki K, Ohya K (2003). Clodronate stimulates bone formation as well as inhibits bone resorption and increases bone mineral density in rats fed a low-calcium diet. J Med Dental Sci. 50: 121–132.
   PubMedGoogle Scholar
• Hu J, Ding M, Søballe K, Bechtold J, Danielsen C, Day J, Hvid I (2002). Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone. 31: 591–597.
   PubMed Web of Science ®Google Scholar
• Im G-I, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004). Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 25: 4105–4115.
   PubMed Web of Science ®Google Scholar
• Izu Y, Sun M, Zwolanek D, Veit G, Williams V, Cha B, Jepsen KJ, Koch M, Birk DE (2011). Type XII collagen regulates osteoblast polarity and communication during bone formation. J Cell Biol. 193: 1115–1130.
   PubMed Web of Science ®Google Scholar
• Jeong HM, Jin Y-H, Choi Y-H, Chung JO, Cho DH, Chung MY, Civitelli R, Chung DJ, Lee KY (2013). Risedronate increases osteoblastic differentiation and function through connexin43. Biochem Biophys Res Commun. 432: 152–156.
   PubMed Web of Science ®Google Scholar
• Kylmäoja E, Kokkonen H, Kauppinen K, Hussar P, Sato T, Haugan K, Larsen BD, Tuukkanen J (2013). Osteoclastogenesis is influenced by modulation of gap junctional communication with antiarrhythmic peptides. Calcif Tissue Int. 92: 270–281.
   PubMed Web of Science ®Google Scholar
• Laing JG, Manley-Markowski RN, Koval M, Civitelli R, Steinberg TH (2001). Connexin45 interacts with zonula occludens-1 and connexin43 in osteoblastic cells. J Biol Chem. 276: 23051–23055.
   PubMed Web of Science ®Google Scholar
• Lecanda F, Towler DA, Ziambaras K, Cheng S-L, Koval M, Steinberg TH, Civitelli R (1998). Gap junctional communication modulates gene expression in osteoblastic cells. Mol Biol Cell. 9: 2249–2258.
   PubMed Web of Science ®Google Scholar
• Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R (2000). Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol. 151: 931–944.
   PubMed Web of Science ®Google Scholar
• Lehenkari PP, Kellinsalmi M, NäPänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, VääNänen HK, Hassinen IE (2002). Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 61: 1255–1262.
   PubMed Web of Science ®Google Scholar
• Lezcano V, Bellido T, Plotkin L, Boland R, Morelli S (2012). Role of connexin 43 in the mechanism of action of alendronate: Dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys. 518: 95–102.
   PubMed Web of Science ®Google Scholar
• Li H, Liu T-F, Lazrak A, Peracchia C, Goldberg GS, Lampe PD, Johnson RG (1996). Properties and regulation of gap junctional hemichannels in the plasma membranes of cultured cells. J Cell Biol. 134: 1019–1030.
   PubMed Web of Science ®Google Scholar
• Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB (1998). Apoptosis during bone-like tissue development in vitro. J Cell Biochem. 68: 31–49.
   PubMed Web of Science ®Google Scholar
• Mashiba T, Turner C, Hirano T, Forwood M, Johnston C, Burr D (2001). Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 28: 524–531.
   PubMed Web of Science ®Google Scholar
• Merrell MA, Wakchoure S, Ilvesaro JM, Zinn K, Gehrs B, Lehenkari PP, Harris KW, Selander KS (2007). Differential effects of Ca2 + on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells. Eur J Pharmacol. 559: 21–31.
   PubMed Web of Science ®Google Scholar
• Miura M, Chen X-D, Allen MR, Bi Y, Gronthos S, Seo B-M, Lakhani S, Flavell RA, Feng X-H, Robey PG (2004). A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 114: 1704–1713.
   PubMed Web of Science ®Google Scholar
• Morelli S, Bilbao PS, Katz S, Lezcano V, RoldáN E, Boland R, Santillan G (2011). Protein phosphatases: possible bisphosphonate binding sites mediating stimulation of osteoblast proliferation. Arch Biochem Biophys. 507: 248–253.
   PubMed Web of Science ®Google Scholar
• Niessen H, Harz H, Bedner P, Kramer K, Willecke K (2000). Selective permeability of different connexin channels to the second messenger inositol 1, 4, 5-trisphosphate. J Cell Sci. 113: 1365–1372.
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004). Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 145: 1835–1841.
   PubMed Web of Science ®Google Scholar
• Pantschenko AG, Zhang W, Nahounou M, Mccarthy MB, Stover ML, Lichtler AC, Clark SH, Gronowicz GA (2005). Effect of osteoblast-targeted expression of Bcl-2 in bone: differential response in male and female mice. J Bone Miner Res. 20: 1414–1429.
   PubMed Web of Science ®Google Scholar
• Pfahnl A, Dahl G (1999). Gating of cx46 gap junction hemichannels by calcium and voltage. Pflügers Arch. 437: 345–353.
   PubMed Web of Science ®Google Scholar
• Pie GN, Czubryt MP (1995). The contribution of ionic contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol. 27: 53–63.
   PubMed Web of Science ®Google Scholar
• Plotkin L, Bellido T (2001). Bisphosphonate-induced, hemichannel-mediated, anti-apoptosis through the Src/ERK pathway: a gap junction-independent action of connexin43. Cell Commun Adhes. 8: 377–382.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005). Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 280: 7317–7325.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T (2008). Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 23: 1712–1721.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Manolagas SC, Bellido T (2002). Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem. 277: 8648–8657.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Manolagas SC, Bellido T (2006). Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 39: 443–452.
   PubMed Web of Science ®Google Scholar
• Qiu C, Coutinho P, Frank S, Franke S, Law L-Y, Martin P, Green CR, Becker DL (2003). Targeting connexin43 expression accelerates the rate of wound repair. Curr Biol. 13: 1697–1703.
   PubMed Web of Science ®Google Scholar
• Rhett JM, Fann SA, Yost MJ (2014). Purinergic signaling in early inflammatory events of the foreign body response: modulating extracellular ATP as an enabling technology for engineered implants and tissues. Tissue Eng Part B Rev.
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JLF, Kashemirov BA (2010). Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res. 25: 606–616.
   PubMed Web of Science ®Google Scholar
• Rogers M (2004). From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 75: 451–461.
   PubMed Web of Science ®Google Scholar
• Russell R, Watts N, Ebetino F, Rogers M (2008). Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 19: 733–759.
   PubMed Web of Science ®Google Scholar
• Shintani-Ishida K, Uemura K, Yoshida K-I (2007). Hemichannels in cardiomyocytes open transiently during ischemia and contribute to reperfusion injury following brief ischemia. Am J Physiol Heart Circ Physiol. 293: H1714–H1720.
   PubMed Web of Science ®Google Scholar
• Siris ES, Pasquale MK, Wang Y, Watts NB (2011). Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008. J Bone Miner Res. 26: 3–11.
   PubMed Web of Science ®Google Scholar
• Storm T, Steiniche T, Thamsborg G, Melsen F (1993). Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 8: 199–208.
   PubMed Web of Science ®Google Scholar
• Unger VM, Kumar NM, Gilula NB, Yeager M (1999). Three-dimensional structure of a recombinant gap junction membrane channel. Science. 283: 1176–1180.
   PubMed Web of Science ®Google Scholar
• van Beek E., Pieterman E, Cohen L, Löwik C, Papapoulos S (1999). Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 264: 108–111.
   PubMed Web of Science ®Google Scholar
• Vashishth D, Verborgt O, Divine G, Schaffler M, Fyhrie D (2000). Decline in osteocyte lacunar density in human cortical bone is associated with accumulation of microcracks with age. Bone. 26: 375–380.
   PubMed Web of Science ®Google Scholar
• von Knoch F., Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS (2005). Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 26: 6941–9.
   PubMed Web of Science ®Google Scholar
• Watkins MP, Norris JY, Grimston SK, Zhang X, Phipps RJ, Ebetino FH, Civitelli R (2012). Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice. Bone. 51: 787–794.
   PubMed Web of Science ®Google Scholar
• Weinstein RS (2000). True strength. J Bone Miner Res. 15: 621–625.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998). Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 102: 274.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Greene P (2013). Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone. 57: 423–428.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Yang H, Feng J, Shi Z, Wu L (2009). Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res. 37: 407–416.
   PubMed Web of Science ®Google Scholar
• Yellowley CE, Li Z, Zhou Z, Jacobs CR, Donahue HJ (2000). Functional gap junctions between osteocytic and osteoblastic cells. J Bone Miner Res. 15: 209–217.
   PubMed Web of Science ®Google Scholar
• Yoshitani K, Kido A, Honoki K, Akahane M, Fujii H, Tanaka Y (2011). Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation. Pathol Res Pract. 207: 417–422.
   PubMed Web of Science ®Google Scholar
• Zhou L, Kasperek EM, Nicholson BJ (1999). Dissection of the molecular basis of pp60v-src induced gating of connexin 43 gap junction channels. J Cell Biol. 144: 1033–1045.
   PubMed Web of Science ®Google Scholar